Antineoplastic Agents: Miscellaneous
OREVL2 “Revlimid capsule” 15 mg/cap
適應症：1. Revlimid與dexamethasone合併使用可治療先前已接受至少一種治療失敗之多發性骨髓瘤(multiple myeloma, MM)患者。2. Revlimid可治療先前尚未接受過任何治療且不適合移植之成年患者。
Usual dose:
Mantle cell lymphoma, Relapse or progression after 2 prior therapies, 1 of which included bortezomib 25 mg ORALLY QD on days 1 through 21 every 28 days Multiple myeloma, In combination with dexamethasone initial dose, 25 mg ORALLY QD with water on days 1 to 21 of a 28-day cycle
Myelodysplastic syndrome, Transfusion-dependent anemia in patients at low or intermediate-1 risk with deletion 5q abnormality 10 mg ORALLY once daily
Myelodysplastic syndrome, Transfusion-dependent anemia in patients at low or intermediate-1 risk without deletion 5q abnormality 5 to 10 mg or 10 mg daily, continuously or for 21 days of every 28-day cycle
Contraindication:
Pregnancy; known teratogen, pregnancy testing required and women of childbearing potential must take adequate precautions to prevent pregnancy for at least 4 weeks prior to initiation of treatment, during treatment, and for at least 4 weeks following discontinuation of treatment
Hypersensitivity to lenalidomide
Adverse effect:
Common: peripheral edema, pruritus, rash, hypokalemia, weight decreased, constipation, diarrhea, nausea, anemia, leukopenia, neutropenia, thrombocytopenia, arthralgia, backache, cramp, asthenia, dizziness, headache, tremor, blurred vision, cough, dyspnea, epistaxis, pharyngitis, upper respiratory infection, fatigue, fever, infectious disease.
Serious: atrial fibrillation, cerebrovascular accident, congestive heart failure, myocardial infarction, syncope, stevens-johnson syndrome, toxic epidermal necrolysis, anemia, deep venous thrombosis, deep venous thrombosis, febrile neutropenia, leukopenia, neutropenia, thrombocytopenia, thrombosis, liver failure, cataract, interstitial nephritis, acute, hypoxia, pleural effusion, pneumonia, pneumonitis, pulmonary embolism, pulmonary hypertension, respiratory distress, angioedema, multiple organ failure, secondary malignant neoplastic disease, tumor flare, tumor lysis syndrome.